The frequency of Epstein-Barr virus among hemodialysis patients, Ahvaz, Iran
-
Rahil Nahid Samiei
,
Shahab Mahmoudvand
,
Somayeh Shokri
,
Manoochehr Makvandi
,
Heshmatollah Shahbazian
,
Roya Pirmoradi
,
Shokouh Shayanpur
,
Kimia Makvandi
,
Sepideh Nowrozi
Abstract
Background and Objectives: Epstein-Barr virus (EBV) has infected more than 90% of adults worldwide. EBV infection is asymptomatic in healthy individuals and is controlled by a robust immune response while in individuals with weakened immunesystems including Hemodialysis (HD) patients and transplant recipients leads to serious illnesses. This study was aimed to investigate the frequency of EBV among the HD patients.
Materials and Methods: The cross-sectional study was carried out on 84 HD patients. These sera were checked for anti-EBV (VCA) IgG Ab assessment using enzyme-linked immunosorbent assay (ELISA). The DNA was extracted from the sera samples and tested for EBV DNA using nested PCR.
Results: 52/84 (61.9%) of HD were males and 32/84 (38.1%) were females. The average age of participants was varying from 18 to 85 years while the mean age was 52 ± 1.57 SD years. 81 of 84 (96.42%); including 49/52 (94.23%) male and 32/32 (100%) female, were positive for anti-EBV (VCA) IgG antibody while 3 (3.58%) were negative. No significant differences were observed between the subjects regarding gender (P=0.28). EBV DNA was detected in 7 (8.33%) individuals, including 6 (11.53%) and 1 (3.12%) in male and female, respectively (P=0.24).
Conclusion: Our study results showed that high prevalence of anti-EBV (VCA) IgG antibody (96.42%) were observed among the HD patients. Although the status of EBV latency was not performed, but it seems many of these patients are at risk of EBV-reactivation during the organ transplantation. As a result, it is recommended that the detection of EBNA-1 gene as a marker of EBV latency should be implemented for all HD patients to prevent EBV reactivation during organ transplantation.
Chabay P, Preciado MV. Epidemiology of Epstein-Barr virus-associated pediatric lymphomas from Argentina. Boletín Médico del Hospital Infantil de México 2016;73(1):47-54.
Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, et al. Spectrum of Epstein-Barr virus-related diseases: a pictorial review. Japanese journal of radiology 2009;27(1):4-19.
Pagano JS. Is Epstein-Barr Virus Transmitted Sexually? The Journal of Infectious Diseases 2007;195(4):469-70.
Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers. Journal of virology 2003;77(3):1840-7.
Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney Transplantation as Primary Therapy for End-Stage Renal Disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) Conference. Clinical Journal of the American Society of Nephrology : CJASN 2008;3(2):471-80.
Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al. Aspects of Immune Dysfunction in End-stage Renal Disease. Clinical Journal of the American Society of Nephrology : CJASN 2008;3(5):1526-33.
Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, et al. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010;95(10):1769-77.
Habib M, Buisson M, Lupo J, Agbalika F, Socié G, Germi R, et al. Lytic EBV infection investigated by detection of Soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD. Scientific Reports 2017;7(1):10479.
Michallet M, Sobh M, Ranchon F, Leroy S, Barraco F, Thomas X, et al. Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies. Blood 2016;128(22):3695-.
Wu C-C, Fang C-Y, Cheng Y-J, Hsu H-Y, Chou S-P, Huang S-Y, et al. Inhibition of Epstein-Barr virus reactivation by the flavonoid apigenin. Journal of Biomedical Science 2017;24(1):2.
Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A. Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment. Cancer Letters 369(1):37-44.
San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH, Meylan P. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clinical Microbiology and Infection 20:109-18.
Gratama JW, Zutter MM, Minarovits J, Oosterveer MA, Thomas ED, Klein G, et al. Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. International journal of cancer 1991;47(2):188-92.
Hassan R, White LR, Stefanoff CG, de Oliveira DE, Felisbino FE, Klumb CE, et al. Epstein-Barr virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma. Diagnostic pathology 2006;1(1):17.
Fishman JA. Infection in renal transplant recipients. Seminars in nephrology 2007 ;27(4):445-61.
Fishman JA. Infection in Solid-Organ Transplant Recipients. New England Journal of Medicine 2007;357(25):2601-14.
McKeown E, Pope JE, Leaf S. Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive. The Open Rheumatology Journal 2009;3:30-4.
Yamamoto T, Nakajima Y, Yamamoto M, Hironaka T, Hirai K, Nakamura Y. Epstein-Barr virus activity in patients on chronic hemodialysis. Nephron 1995;70(4):449-54.
Nikoobakht M, Beitollahi J, Nikoobakht N, Aloosh M, Sahebjamee M, Rezaeidanesh M, et al. Evaluation of Epstein–Barr Virus Load in Saliva Before and After Renal Transplantation. Transplantation Proceedings 2011;43(2):540-2.
Vilibić-Čavlek T, Kolarić B, Bogdanić M, Tabain I, Beader N. Herpes Group Viruses: a Seroprevalence Study in Hemodialysis Patients. Acta clinica Croatica 2017;56(2.):255-61.
Beader N, Kolaric B, Slacanac D, Tabain I, Vilibic-Cavlek T. Seroepidemiological Study of Epstein-Barr Virus in Different Population Groups in Croatia. The Israel Medical Association journal : IMAJ 2018;20(2):86-90.
Saghafi H, Qorashi M, Heidari A. Is Screening for IgG Antibody to Cytomegalovirus and Epstein-Barr Virus Infections Mandatory in Potential Renal Transplant Recipients and Donors in Iran? Transplantation Proceedings 2009;41(7):2761-3.
Beladi Mousavi SS. Do we need to screen our patients for EBV IgG antibody before kidney transplantation? Nephrourol Mon 2011;3(2):122-4.
Hasannia T, Moosavi Movahed SM, Vakili R, Rafatpanah H, Hekmat R, Valizadeh N, et al. Active CMV and EBV infections in renal transplant recipients with unexplained fever and elevated serum creatinine. Renal Failure 2016;38(9):1418-24.
Babel N, Schwarzmann F, Prang N, Jaeger M, Wolf H, Kern F, et al. Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients. Transplantation 2001;72(4):736-9.
Ahya VN, Douglas LP, Andreadis C, Arnoldi S, Svoboda J, Kotloff RM, et al. Association Between Elevated Whole Blood Epstein–Barr Virus (EBV)-encoded RNA EBV Polymerase Chain Reaction and Reduced Incidence of Acute Lung Allograft Rejection. The Journal of Heart and Lung Transplantation 2007;26(8):839-44.
Rohr JC, Wagner HJ, Lauten M, Wacker HH, Juttner E, Hanke C, et al. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatric transplantation 2008;12(4):426-31.
Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Léonard P, Moreels A, et al. Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double- Blind, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein- Barr Virus Vaccine in Healthy Young Adults. The Journal of Infectious Diseases 2007;196(12):1749-53.
Martinez OM, Krams SM. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder. Transplantation 2017;101(9):2009-16.
Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, et al. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients. Pediatric nephrology 2017;32(8):1433-42.
Gill H, Hwang Y-Y, Chan TSY, Pang AWK, Leung AYH, Tse E, et al. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab. Journal of Clinical Virology 2014;59(4):255-8.
| Files | ||
| Issue | Vol 11 No 1 (2019) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijm.v11i1.709 | |
| Keywords | ||
| Epstein-Barr virus Hemodialysis patients Enzyme-linked immunosorbent assay | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
